The Zhitong Finance App learned that Goldman Sachs released a research report stating that it gave the “buy” rating to Shiyao Group (01093), the net profit forecast for this year and next two years was raised by 1.1% and 7%, respectively, and the target price was raised from HK$9.24 to HK$9.73. Last quarter, Shijiao's EBIT exceeded this forecast, rising 13% year over year to RMB 1.77 billion.

According to the report, CSPC Group's sales increased 1.9% year-on-year to 7.6 billion yuan in the previous quarter, in line with expectations. During the period, although the product “Ke Aili” (Ke Aili) was affected by drug collection policies, the Group's launch of new products such as Irinotecan liposome injection (Irinotecan liposome) helped offset some of the effects.